<p><strong><em>与国家最大的军事医疗中心的合作专注于 bioAffinity Technologies 的解决方案管道，以应对严重的呼吸系统疾病</em></strong></p>
<p><strong><em>研究将探索针对哮喘和慢性阻塞性肺病（COPD）治疗市场（估计为 920 亿美元）的一种专有流式细胞术 + 人工智能诊断测试的潜力</em></strong></p>
<p>圣安东尼奥 --（商业资讯）-- <strong>bioAffinity Technologies, Inc.</strong> <strong>（纳斯达克：BIAF；BIAFW）</strong>，一家推进肺癌和其他肺部疾病非侵入性诊断的生物技术公司，今天宣布与布鲁克军医中心（BAMC）进行一项试点研究，以评估公司正在开发的专有测试，旨在识别哮喘和慢性阻塞性肺病（COPD）的特定炎症生物标志物。该研究可能导致诊断测试的开发，旨在帮助将患者与最有效的治疗方案相匹配，并帮助监测药物的有效性。</p>
<p>与 BAMC 的研究合作建立在 bioAffinity Technologies 的研究管道基础上，利用其专有的流式细胞术 + 人工智能技术，通过评估肺部炎症的程度和类型，开发针对常见气道疾病的精准诊断和治疗方案。</p>
<p>“在过去十年中，我们在理解哮喘和 COPD 的病理生理学方面取得了巨大的进展，” 约翰·J·奥本海默（John J. Oppenheimer）医学博士说，他是哮喘和 COPD 诊断与治疗的权威，并且是新泽西州医药与牙科大学 - 罗格斯大学的教授。奥本海默博士还担任 bioAffinity Technologies 董事会成员。“新兴工具——例如 bioAffinity 的细胞术 + 人工智能平台——可能会通过直接评估患者肺部的炎症环境来加速这一进展。通过这种分辨率，我们可以更好地分层疾病进展的风险，并更准确地将合适的药物匹配给合适的患者。”</p>
<p>该研究将招募大约 40 名参与者，分为三个组别：哮喘患者、COPD 患者和健康对照组。研究的目标是使用自动化分析从哮喘和 COPD 患者收集的痰样本，以识别和测量痰中的特定免疫细胞群体和细胞因子，从而指导治疗并监测疗法的有效性。</p>
<p>哮喘并不是单一的疾病。它包括多种炎症亚型。在军人中，哮喘通常不是在平民人群中看到的经典过敏型，因此诊断和治疗更具挑战性。军人面临各种环境、职业和部署相关的危害，这些危害可能根本改变哮喘的表现和进展。</p>
<p>“我们的流式细胞术平台提供了一种新颖的、非侵入性的方法来评估细胞水平的肺部炎症，” bioAffinity Technologies 的首席医学官戈登·唐尼（Gordon Downie）医学博士说。“通过识别更广泛的炎症生物标志物面板，我们希望将哮喘和 COPD 的管理转向精准医学模型，在这种模型中，治疗是根据每个患者独特的炎症特征来指导的，而不是一刀切的方法。我们的技术还有潜力帮助医生监测治疗反应的变化，从而改善患者的治疗结果。”</p>
<p>BAMC 研究的目标是确定公司的肺部炎症测试，包括流式细胞术和酶联免疫吸附测定（ELISA）分析，是否可以帮助医生量身定制更有效的哮喘和 COPD 治疗策略。在军事背景下，一种安全、可靠的非侵入性评估肺部炎症的方法可能会对军人和退伍军人的战备和部署决策以及长期呼吸健康结果产生积极影响。</p>
<p><strong>关于 CyPath® Lung</strong></p>
<p>bioAffinity Technologies 的 CyPath® Lung 是一种非侵入性测试，旨在改善高风险患者早期肺癌的检测。CyPath® Lung 使用先进的流式细胞术和专有的人工智能（AI）来识别患者痰液中指示恶性肿瘤的细胞群体。CyPath® Lung 包含一种荧光卟啉，优先被癌细胞和癌相关细胞吸收。在一项针对高风险患者的临床试验中，CyPath® Lung 在检测高风险患者中小于 20 毫米的肺结节时，显示出 92% 的敏感性、87% 的特异性、88% 的准确性和 99% 的阴性预测值（NPV）。高 NPV 使医生更有信心认为阴性结果确实为阴性，从而可能使患者免于不必要的侵入性和昂贵的程序。CyPath® Lung 被作为实验室开发测试（LDT）进行市场推广，并不打算作为唯一的诊断工具，应该与其他临床发现一起考虑。</p>
<p><strong>关于 bioAffinity Technologies, Inc.</strong></p>
<p>bioAffinity Technologies, Inc. 满足对早期癌症和其他肺部疾病的非侵入性诊断以及广谱癌症治疗的需求。公司的第一款产品 CyPath® Lung 是一种非侵入性测试，已显示出对早期肺癌检测的高敏感性、特异性和准确性。CyPath® Lung 由 bioAffinity Technologies 的子公司 Precision Pathology Laboratory Services 作为实验室开发测试（LDT）进行市场推广。LDT 在临床实验室改进修正案（CLIA）下进行监管，由医疗保险和医疗补助服务中心管理。有关更多信息，请访问 www.bioaffinitytech.com。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿中的某些声明构成联邦证券法意义上的 “前瞻性声明”。诸如 “可能”、“或许”、“将”、“应该”、“相信”、“期望”、“预期”、“估计”、“继续”、“预测”、“展望”、“计划”、“打算” 或类似表达，或关于意图、信念或当前预期的声明，均为前瞻性声明。这些前瞻性声明受到各种风险和不确定性的影响，其中许多是难以预测的，这可能导致实际结果与当前预期和假设显著不同于任何前瞻性声明中所列或暗示的内容。可能导致实际结果与当前预期显著不同的重要因素包括但不限于：公司哮喘和慢性阻塞性肺病研究的早期阶段及其结果的不确定性；开发和商业化新诊断测试的能力；公司产品的监管状态，包括实验室开发测试的不断变化的监管框架及 FDA 监督可能增加的潜力；需要获得未来产品的监管许可或批准，包括任何伴随诊断；公司在临床研究中招募参与者的能力；公司对第三方合作伙伴的依赖，包括军事医疗机构；呼吸道诊断的竞争格局；公司保护其知识产权的能力；以及在公司截至 2025 年 12 月 31 日的 10-K 表格年度报告及其后续向 SEC 提交的文件中讨论的其他因素，包括后续的 10-Q 和 8-K 表格定期报告。这些前瞻性声明是基于在作出这些声明时存在的事实和条件以及对未来事实和条件的预测。虽然公司认为这些前瞻性声明是合理的，但本新闻稿的读者应谨慎对待任何前瞻性声明，不应过度依赖。本发布的信息仅在发布之日提供，公司不承担更新与本新闻稿中讨论事项相关的任何前瞻性声明的义务，除非适用的证券法要求。</p>
<p>1 Grand View Research，慢性阻塞性肺病和哮喘治疗市场（2025 - 2030）</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjA0Mjg5OTAxMzByMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjA0Mjg5OTAxMzByMQ"/></p>
<p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20260428990130/en/</p>
<p>bioAffinity Technologies</p>
<p>Julie Anne Overton</p>
<p>传播总监</p>
<p>investors@bioaffinitytech.com</p>
<p>来源：bioAffinity Technologies, Inc.</p>

BIAF

BIAFW

动态生物技术与基因组 ETF - Invesco

纽交所高增长板生物技术指数 ETF - First Trust

医药突破 ETF - ALPS

标普生物技术 3 倍做多 - Direxion

生物科技 ETF - VanEck Vectors

2 倍做多纳斯达克生物技术 ETF - ProShares

标普生物技术 ETF - SPDR

纳斯达克生物科技指数 ETF - iShares Nasdaq

<p>bioAffinity Technologies, Inc.（纳斯达克代码：BIAF）已与布鲁克陆军医疗中心合作启动了一项试点研究，以评估其流式细胞术 + 人工智能诊断测试在哮喘和慢性阻塞性肺病（COPD）中的应用。该研究旨在识别炎症生物标志物，以便为这些影响重大市场的呼吸系统疾病量身定制治疗方案。预计将招募约 40 名参与者，分析痰样本中的免疫细胞群体和细胞因子。目标是提升哮喘和 COPD 管理中的精准医疗，特别是针对军人，提高治疗效果和呼吸健康</p>

<p><strong><em>Collaboration with nation’s largest military medical center focuses on bioAffinity Technologies’ pipeline of solutions to address debilitating respiratory diseases</em></strong></p>
<div class="lb-trans"><p><strong><em>与国家最大的军事医疗中心的合作专注于 bioAffinity Technologies 的解决方案管道，以应对严重的呼吸系统疾病</em></strong></p>
</div><p><strong><em>Study to explore the potential for proprietary flow cytometry+AI diagnostic tests targeting the asthma and COPD treatment market estimated at $92 billion1</em></strong></p>
<div class="lb-trans"><p><strong><em>研究将探索针对哮喘和慢性阻塞性肺病（COPD）治疗市场（估计为 920 亿美元）的一种专有流式细胞术 + 人工智能诊断测试的潜力</em></strong></p>
</div><p>SAN ANTONIO--(BUSINESS WIRE)-- <strong>bioAffinity Technologies, Inc.</strong> <strong>(Nasdaq: BIAF; BIAFW)</strong>,a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced a pilot study with Brooke Army Medical Center (BAMC) to evaluate the Company’s proprietary tests under development to identify specific inflammatory biomarkers for asthma and chronic obstructive pulmonary disease (COPD). The study could lead to the development of diagnostic tests designed to help align patients with the most effective treatments and help monitor the drugs’ effectiveness over time.</p>
<div class="lb-trans"><p>圣安东尼奥 --（商业资讯）-- <strong>bioAffinity Technologies, Inc.</strong> <strong>（纳斯达克：BIAF；BIAFW）</strong>，一家推进肺癌和其他肺部疾病非侵入性诊断的生物技术公司，今天宣布与布鲁克军医中心（BAMC）进行一项试点研究，以评估公司正在开发的专有测试，旨在识别哮喘和慢性阻塞性肺病（COPD）的特定炎症生物标志物。该研究可能导致诊断测试的开发，旨在帮助将患者与最有效的治疗方案相匹配，并帮助监测药物的有效性。</p>
</div><p>The research collaboration with BAMC builds on bioAffinity Technologies’ research pipeline, leveraging its proprietary flow cytometry+AI technology to develop precision diagnostics and treatments for common airway diseases by assessing the extent and type of lung inflammation.</p>
<div class="lb-trans"><p>与 BAMC 的研究合作建立在 bioAffinity Technologies 的研究管道基础上，利用其专有的流式细胞术 + 人工智能技术，通过评估肺部炎症的程度和类型，开发针对常见气道疾病的精准诊断和治疗方案。</p>
</div><p>“We have made tremendous strides over the last decade in our understanding of the pathophysiology of asthma and COPD,” said John J. Oppenheimer, MD, a leading authority on the diagnosis and treatment of asthma and COPD and professor at the University of Medicine and Dentistry of New Jersey-Rutgers. Dr. Oppenheimer also sits on the bioAffinity Technologies Board of Directors. “Emerging tools – such as bioAffinity’s cytometry+AI platform – will likely accelerate this progress by enabling direct assessment of a patient’s inflammatory milieu within the lung. With this level of resolution, we can better stratify the risk of disease progression and more accurately match the right medicine to the right patient.”</p>
<div class="lb-trans"><p>“在过去十年中，我们在理解哮喘和 COPD 的病理生理学方面取得了巨大的进展，” 约翰·J·奥本海默（John J. Oppenheimer）医学博士说，他是哮喘和 COPD 诊断与治疗的权威，并且是新泽西州医药与牙科大学 - 罗格斯大学的教授。奥本海默博士还担任 bioAffinity Technologies 董事会成员。“新兴工具——例如 bioAffinity 的细胞术 + 人工智能平台——可能会通过直接评估患者肺部的炎症环境来加速这一进展。通过这种分辨率，我们可以更好地分层疾病进展的风险，并更准确地将合适的药物匹配给合适的患者。”</p>
</div><p>The study will enroll approximately 40 participants in three cohorts: patients with asthma, patients with COPD and a healthy control group. The objective of the study is to use automated analysis of sputum samples collected from patients with asthma and COPD to identify and measure select immune cell populations and cytokines in sputum that can direct treatment and monitor the effectiveness of therapies.</p>
<div class="lb-trans"><p>该研究将招募大约 40 名参与者，分为三个组别：哮喘患者、COPD 患者和健康对照组。研究的目标是使用自动化分析从哮喘和 COPD 患者收集的痰样本，以识别和测量痰中的特定免疫细胞群体和细胞因子，从而指导治疗并监测疗法的有效性。</p>
</div><p>Asthma is not a single disease. It includes multiple inflammatory subtypes. In military personnel, asthma is generally not the classic allergic form seen in civilian populations, making diagnosis and treatment more challenging. Service members are exposed to a wide range of environmental, occupational and deployment-related hazards that can fundamentally alter how asthma presents and progresses.</p>
<div class="lb-trans"><p>哮喘并不是单一的疾病。它包括多种炎症亚型。在军人中，哮喘通常不是在平民人群中看到的经典过敏型，因此诊断和治疗更具挑战性。军人面临各种环境、职业和部署相关的危害，这些危害可能根本改变哮喘的表现和进展。</p>
</div><p>“Our flow cytometry platform provides a novel, noninvasive way to assess lung inflammation at the cellular level,” said Gordon Downie, MD, PhD, bioAffinity Technologies’ Chief Medical Officer. “By identifying a broader panel of inflammatory biomarkers, we hope to help shift asthma and COPD management toward a precision medicine model, where treatment is guided by each patient’s unique inflammatory signature rather than a one-size-fits-all approach. Our technology also has the potential to help physicians monitor treatment response over time, improving patient outcomes.”</p>
<div class="lb-trans"><p>“我们的流式细胞术平台提供了一种新颖的、非侵入性的方法来评估细胞水平的肺部炎症，” bioAffinity Technologies 的首席医学官戈登·唐尼（Gordon Downie）医学博士说。“通过识别更广泛的炎症生物标志物面板，我们希望将哮喘和 COPD 的管理转向精准医学模型，在这种模型中，治疗是根据每个患者独特的炎症特征来指导的，而不是一刀切的方法。我们的技术还有潜力帮助医生监测治疗反应的变化，从而改善患者的治疗结果。”</p>
</div><p>The goal of the BAMC study is to determine whether the Company’s lung inflammation tests, including flow cytometry and enzyme-linked immunosorbent assay (ELISA) analysis, can help physicians tailor more effective treatment strategies for asthma and COPD. In the military context, a safe, reliable noninvasive way to assess lung inflammation could positively impact readiness and deployment decisions as well as long-term respiratory health outcomes for service members and veterans.</p>
<div class="lb-trans"><p>BAMC 研究的目标是确定公司的肺部炎症测试，包括流式细胞术和酶联免疫吸附测定（ELISA）分析，是否可以帮助医生量身定制更有效的哮喘和 COPD 治疗策略。在军事背景下，一种安全、可靠的非侵入性评估肺部炎症的方法可能会对军人和退伍军人的战备和部署决策以及长期呼吸健康结果产生积极影响。</p>
</div><p><strong>About CyPath® Lung</strong></p>
<div class="lb-trans"><p><strong>关于 CyPath® Lung</strong></p>
</div><p>CyPath® Lung by bioAffinity Technologies is a noninvasive test designed to improve the early detection of lung cancer in patients at high risk for the disease. CyPath® Lung uses advanced flow cytometry and proprietary artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. CyPath® Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. In a clinical trial of high-risk patients, CyPath® Lung demonstrated 92% sensitivity, 87% specificity, 88% accuracy and 99% negative predictive value (NPV) in detecting lung cancer in patients at high risk for the disease who had small indeterminate lung nodules less than 20 millimeters. The high NPV gives physicians greater confidence that a negative result is truly negative, potentially sparing patients from unnecessary invasive and costly procedures. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) and is not intended for use as a sole diagnostic tool and should be considered alongside other clinical findings.</p>
<div class="lb-trans"><p>bioAffinity Technologies 的 CyPath® Lung 是一种非侵入性测试，旨在改善高风险患者早期肺癌的检测。CyPath® Lung 使用先进的流式细胞术和专有的人工智能（AI）来识别患者痰液中指示恶性肿瘤的细胞群体。CyPath® Lung 包含一种荧光卟啉，优先被癌细胞和癌相关细胞吸收。在一项针对高风险患者的临床试验中，CyPath® Lung 在检测高风险患者中小于 20 毫米的肺结节时，显示出 92% 的敏感性、87% 的特异性、88% 的准确性和 99% 的阴性预测值（NPV）。高 NPV 使医生更有信心认为阴性结果确实为阴性，从而可能使患者免于不必要的侵入性和昂贵的程序。CyPath® Lung 被作为实验室开发测试（LDT）进行市场推广，并不打算作为唯一的诊断工具，应该与其他临床发现一起考虑。</p>
</div><p><strong>About bioAffinity Technologies, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 bioAffinity Technologies, Inc.</strong></p>
</div><p>bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. LDTs are overseen under the Clinical Laboratory Improvement Amendments (CLIA), administered by the Centers for Medicare &amp; Medicaid Services. For more information, visit www.bioaffinitytech.com.</p>
<div class="lb-trans"><p>bioAffinity Technologies, Inc. 满足对早期癌症和其他肺部疾病的非侵入性诊断以及广谱癌症治疗的需求。公司的第一款产品 CyPath® Lung 是一种非侵入性测试，已显示出对早期肺癌检测的高敏感性、特异性和准确性。CyPath® Lung 由 bioAffinity Technologies 的子公司 Precision Pathology Laboratory Services 作为实验室开发测试（LDT）进行市场推广。LDT 在临床实验室改进修正案（CLIA）下进行监管，由医疗保险和医疗补助服务中心管理。有关更多信息，请访问 www.bioaffinitytech.com。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>Certain statements in this press release constitute &#34;forward-looking statements&#34; within the meaning of the federal securities laws. Words such as &#34;may,&#34; &#34;might,&#34; &#34;will,&#34; &#34;should,&#34; &#34;believe,&#34; &#34;expect,&#34; &#34;anticipate,&#34; &#34;estimate,&#34; &#34;continue,&#34; &#34;predict,&#34; &#34;forecast,&#34; &#34;project,&#34; &#34;plan,&#34; &#34;intend&#34; or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the early stage of the Company's asthma and COPD study and the uncertainty of its results; the ability to develop and commercialize new diagnostic tests; the regulatory status of the Company's products, including the evolving regulatory framework for Laboratory Developed Tests and the potential for increased FDA oversight; the need to obtain regulatory clearances or approvals for future products, including any companion diagnostics; the Company's ability to enroll participants in clinical studies; the Company's reliance on third-party collaborators, including military medical institutions; the competitive landscape for respiratory diagnostics; the Company's ability to protect its intellectual property; and the other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.</p>
<div class="lb-trans"><p>本新闻稿中的某些声明构成联邦证券法意义上的 “前瞻性声明”。诸如 “可能”、“或许”、“将”、“应该”、“相信”、“期望”、“预期”、“估计”、“继续”、“预测”、“展望”、“计划”、“打算” 或类似表达，或关于意图、信念或当前预期的声明，均为前瞻性声明。这些前瞻性声明受到各种风险和不确定性的影响，其中许多是难以预测的，这可能导致实际结果与当前预期和假设显著不同于任何前瞻性声明中所列或暗示的内容。可能导致实际结果与当前预期显著不同的重要因素包括但不限于：公司哮喘和慢性阻塞性肺病研究的早期阶段及其结果的不确定性；开发和商业化新诊断测试的能力；公司产品的监管状态，包括实验室开发测试的不断变化的监管框架及 FDA 监督可能增加的潜力；需要获得未来产品的监管许可或批准，包括任何伴随诊断；公司在临床研究中招募参与者的能力；公司对第三方合作伙伴的依赖，包括军事医疗机构；呼吸道诊断的竞争格局；公司保护其知识产权的能力；以及在公司截至 2025 年 12 月 31 日的 10-K 表格年度报告及其后续向 SEC 提交的文件中讨论的其他因素，包括后续的 10-Q 和 8-K 表格定期报告。这些前瞻性声明是基于在作出这些声明时存在的事实和条件以及对未来事实和条件的预测。虽然公司认为这些前瞻性声明是合理的，但本新闻稿的读者应谨慎对待任何前瞻性声明，不应过度依赖。本发布的信息仅在发布之日提供，公司不承担更新与本新闻稿中讨论事项相关的任何前瞻性声明的义务，除非适用的证券法要求。</p>
</div><p>1 Grand View Research, COPD And Asthma Therapeutics Market (2025 - 2030)</p>
<div class="lb-trans"><p>1 Grand View Research，慢性阻塞性肺病和哮喘治疗市场（2025 - 2030）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjA0Mjg5OTAxMzByMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260428990130r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20260428990130/en/</p>
<div class="lb-trans"><p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20260428990130/en/</p>
</div><p>bioAffinity Technologies</p>
<div class="lb-trans"><p>bioAffinity Technologies</p>
</div><p>Julie Anne Overton</p>
<div class="lb-trans"><p>Julie Anne Overton</p>
</div><p>Director of Communications</p>
<div class="lb-trans"><p>传播总监</p>
</div><p>investors@bioaffinitytech.com</p>
<div class="lb-trans"><p>investors@bioaffinitytech.com</p>
</div><p>Source: bioAffinity Technologies, Inc.</p>
<div class="lb-trans"><p>来源：bioAffinity Technologies, Inc.</p>
</div>

bioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and Treatment | BIAF Stock News

StockTitan

bioAffinity Tech

BIOAFFINITY TECHNOLOGIES INC C/WTS 07/09/2027 (TO PUR COM)

bioAffinity Technologies 启动新研究，旨在扩大 CyPath® Lung 技术在哮喘和慢性阻塞性肺病（COPD）诊断和治疗中的应用 | BIAF 股票新闻